| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,000 | 6,150 | 26.06. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 16,000 | 500 | |||
| 15,000 | 15 | |||
| 7,800 | 400 | |||
| 6,150 | 626 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 626 | 6,050 | |||
| 191 | 5,100 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.878 | 0,857 | 1.610 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 273 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 15.06. | 4basebio appoints Dr Jeff Coller to advisory board | 2 | Sharecast | ||
| 15.06. | 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | 139 | GlobeNewswire (Europe) | Dr. Coller,a Bloomberg Distinguished Professor of RNA Biology and Therapeutics, brings deep expertise to accelerate synthetic DNA and mRNA manufacturingDr. Coller's laboratory team has made seminal... ► Artikel lesen | |
| 15.06. | 4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | 297 | PR Newswire | 4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
PR Newswire
LONDON, United Kingdom, June 15
4basebio... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 00:35 | Onco-Innovations leitet Studien zur Verstoffwechselung von ONC010 in Hepatozyten und Lebermikrosomen aus drei Tierarten ein | IR-WORLD | Vancouver, Kanada - 26. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") kündigt die Einleitung von Studien... ► Artikel lesen | |
| Fr | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| Fr | Swedish Orphan Biovitrum AB: Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase) | PR Newswire | STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety... ► Artikel lesen | |
| 00:02 | Onco-Innovations Limited: Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / June 26, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the initiation of hepatocyte and... ► Artikel lesen | |
| 03:02 | Telo Genomics Corp.: Telo Genomics Announces Termination of Investor Relations Agreement | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen |